Assess the safety, tolerability and pharmacokinetics of AZD5055 following single and multiple ascending doses in healthy participants

Study identifier:D8960C00001

ClinicalTrials.gov identifier:NCT05134727

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Double-blind, Randomized, Placebo-controlled Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of oral AZD5055 Following Single and Multiple Ascending Doses

Medical condition

Idiopathic Pulmonary Fibrosis

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD5055, Placebo

Sex

All

Actual Enrollment

63

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 18 Nov 2021
Primary Completion Date: 31 Mar 2023
Study Completion Date: 31 Mar 2023

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 May 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria